An observational study in Community Acquired Pneumonia, sponsored by Capnetz Stiftung. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Capnetz Stiftung · Observational
The main objective of this study is to investigate prevalence and risk factors for community-acquired pneumonia (CAP) and its interaction with comorbidities in an unselected group of adult patients receiving outpatient and inpatient care. In addition, information on HIV as a risk factor for CAP and on CAP in immunocompromised patients is collected.
The CAPNETZ study is a prospective, multicenter observational study investigating community-acquired pneumonia (CAP). Patients are recruited from outpatient and inpatient settings at hospitals and from primary care physicians (primarily specialists) and are followed for a period of six months. All CAP patients who meet the inclusion and exclusion criteria, consent to participate, and in whom the presence of a newly developed, community-acquired pneumonia can be verified are invited to participate. The baseline examination includes a detailed medical history, medication history, and a physical examination to record clinical and vital signs. In addition, the results of routine clinical imaging are documented, and biosamples (blood, urine, and respiratory specimens) are collected for clinical chemistry and microbiological analysis. Further in-person visits to document the course of the disease and treatment, including the collection of additional blood samples, take place 3 and 7 days after study enrollment. Twenty-eight days after enrollment, the patient's health status, treatment course, and complications are assessed by telephone. Finally, after 180 days, a telephone survey is conducted to determine the patient's whereabouts and survival status. Apart from the collection of biomaterials, no interventions are required or planned; physicians treat their patients as they normally would.
324 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.
This study's planned enrollment of 20,000 is above the median of 650 across 111 observational studies indexed under Community-Acquired Pneumonia.
Browse Community-Acquired Pneumonia studies →This is the only study on the registry with Capnetz Stiftung as lead sponsor.
Counted across the registry records on this site, refreshed daily.
patients with pneumonia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
diagnosis
Assessment of diagnosis: Patients will be asked for example, about their diagnosis, comorbidities, specific risk factors and pneumonia symptoms.
Time frame: 2 weeks
therapy
Assessment of therapy: Patients will be asked about their therapy due to pneumonia symptoms, previous therapy, medication History etc.
Time frame: 2 weeks
hospitalization
Assessment of hospitalization: Patients will be asked about hospitalization, date, time and duration of hospitalization due to pneumonia symptoms.
Time frame: 2 weeks
Plan to share: Yes — All individual non-personal data and biomaterials collected as part of the study are available for use. This requires a formal request that describes a specific research project and specifies the data needed. Applications have to be submitted on https://capnetz.de/en/project-application/ . Upon approval by the Executive Board, the relevant data and biomaterials will be provided.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Community-Acquired Pneumonia →